Boston Scientific’s Strategic Growth and Financial Resilience Underpin Buy Rating

Analyst Travis Steed from Bank of America Securities maintained a Buy rating on Boston Scientific (BSX – Research Report) and keeping the price target at $115.00.

Travis Steed has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong financial performance and strategic positioning. The company has demonstrated robust revenue growth and margin durability, even in the face of a $200 million tariff headwind, which has been partially alleviated by lower China rates. Boston Scientific’s commitment to reinvestment and operating margin improvement further supports its financial health.
Moreover, the company’s strategic initiatives, such as the acquisitions of Bolt and SoniVie, and its focus on expanding into high-growth areas like electrophysiology, underpin its long-term growth prospects. Boston Scientific’s leadership in the electrophysiology market, particularly with its Farapulse technology, positions it well to capitalize on significant revenue opportunities. The anticipated new long-range plan to be presented by the incoming CFO, along with the company’s consistent execution and innovation, reinforces confidence in its ability to sustain high growth relative to peers.